All In Biotech

Drug Trial Radar · NCT01830660

A Phase I Study of Hetrombopag Olamine in Healthy Adult Volunteers

A Phase I, Randomized, Placebo-controlled, Ascending Single And Multiple Oral Dose Study To Investigate Safety, Tolerability, Pharmacokinetics, And Pharmacodynamics Of Hetrombopag Olamine (SHR8735 Olamine) In Healthy Subjects

Last checked: Nov 20, 2026Latest source record: Apr 6, 2015 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

96

Planned (sponsor's estimate)

Start

Apr 2012

Primary completion

Jun 2013

Study completion Jun 2013

Sponsor

Sponsor type
Industry
First posted
Apr 12, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
Who can join
Male only, from 18 years, up to 45 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Hetrombopag Olamine made by Jiangsu Hengrui Medicine co Ltd. has shown an effect of increasing platelet count in animal and human. This study is designed in dose escalation fashion to evaluate safety, pharmacokinetics and efficacy of Hetrombopag Olamine.

Conditions

  • Healthy

Interventions

  • Hetrombopag Olamine TabletsDrug

  • placeboDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change in platelet count above baseline(%)on Day1,3,5,8,10,12,15,17,19,22,25,28 after dosingTime frame: up to 4 weeks
  2. Composite pharmacokinetic (PK) parameters of eltrombopag following a single dose of eltrombopagTime frame: For 5 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • West China Hospital, Sichuan University

    Chengdu, Sichuan, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.